LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announces the departure of Philippe Calais, PhD. Pharm., Neurochem's President, Global Business. Dr. Calais joined Neurochem in 2003, and is leaving effective December 31, 2007, to pursue other interests.
"Dr. Calais has made a significant contribution to creating constructive relationships for Neurochem in international markets and we are grateful for having had the benefit of his expertise during the five years he has been with us," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. "We wish him every success in his new pursuits."
Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to patients suffering from serious diseases.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit the Web Site at: http://www.neurochem.com.
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute forward-looking statements. Such statements, based as they
are on the current expectations of management, inherently involve numerous
risks and uncertainties, known and unknown, many of which are beyond
Neurochem's control. Such risks include but are not limited to: the impact
of general economic conditions, general conditions in the pharmaceutical
and/or nutraceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem does business, stock market volatility,
fluctuations in costs, and changes to the competitive environment due to
consolidation, that actual results may vary once the final and
quality-controlled verification of data a
|SOURCE NEUROCHEM INC.|
Copyright©2007 PR Newswire.
All rights reserved